Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2020

Open Access 01-12-2020 | Prostate Cancer | Case report

Unexpected tumor response to palliative pelvic radiotherapy in mismatch repair-deficient advanced prostate cancer: a case report

Authors: Giovanni Aluisio, Ercole Mazzeo, Frank Lohr, Federica Fiocchi, Stefania Bettelli, Cinzia Baldessari, Maurizio Paterlini, Alessio Bruni

Published in: Journal of Medical Case Reports | Issue 1/2020

Login to get access

Abstract

Background

Mismatch-repair-deficiency resulting in microsatellite instability (MSI) may confer increased radiosensitivity in locally advanced/metastatic tumors and thus radiotherapy (RT) potentially might have a changing role in treating this subset of patients, alone or in combination with checkpoint inhibitors.

Case presentation

We report a 76 year-old Italian male patient presenting with locally advanced undifferentiated prostate cancer (LAPC), infiltrating bladder and rectum. Molecular analysis revealed high-MSI with an altered expression of MSH2 and MSH6 at immunohistochemistry. Two months after 6 chemotherapy cycles with Docetaxel associated to an LHRH analogue, a computed tomography scan showed stable disease. After palliative RT (30 Gy/10 fractions) directed to the tumor mass with a 3D-conformal setup, a follow-up computed tomography scan at 8 weeks revealed an impressive response that remained stable at computed tomography after 9 months, with sustained biochemical response. To our knowledge, this is the first case of such a sustained response to low dose RT alone in high-MSI LAPC.

Conclusions

Routine evaluation of MSI in patients with locally problematic advanced tumors might change treatment strategy and treatment aim in this setting, from a purely palliative approach to a quasi-curative paradigm.
Literature
3.
go back to reference Fraune C, Simon R, Höflmayer D, Möller K, Dum D, Büscheck F, Hube-Magg C, Makrypidi-Fraune G, Kluth M, Hinsch A, Burandt E, Clauditz TS, Wilczak W, Sauter G, Steurer S. High homogeneity of mismatch repair deficiency in advanced prostate cancer. Virchows Arch. 2020;476:745–52.CrossRef Fraune C, Simon R, Höflmayer D, Möller K, Dum D, Büscheck F, Hube-Magg C, Makrypidi-Fraune G, Kluth M, Hinsch A, Burandt E, Clauditz TS, Wilczak W, Sauter G, Steurer S. High homogeneity of mismatch repair deficiency in advanced prostate cancer. Virchows Arch. 2020;476:745–52.CrossRef
6.
go back to reference Arai M, Ban S, Kakinuma S, Igo M, Tsuji A, Sugyo A, Miyaki M, Miki M, Imai T, Shimadamasami Y, Miki Y, Taka YS. Mismatch repair deficiency and radiosensitivity in colon cancer cell lines. J Radiat Res. Arai M, Ban S, Kakinuma S, Igo M, Tsuji A, Sugyo A, Miyaki M, Miki M, Imai T, Shimadamasami Y, Miki Y, Taka YS. Mismatch repair deficiency and radiosensitivity in colon cancer cell lines. J Radiat Res.
14.
go back to reference FDA Approval History. Keytruda (pembrolizumab) FDA Approval History. Drugs.com. FDA Approval History. Keytruda (pembrolizumab) FDA Approval History. Drugs.com.
19.
go back to reference Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys. 2012;84:879–80.CrossRef Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys. 2012;84:879–80.CrossRef
Metadata
Title
Unexpected tumor response to palliative pelvic radiotherapy in mismatch repair-deficient advanced prostate cancer: a case report
Authors
Giovanni Aluisio
Ercole Mazzeo
Frank Lohr
Federica Fiocchi
Stefania Bettelli
Cinzia Baldessari
Maurizio Paterlini
Alessio Bruni
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2020
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-020-02578-4

Other articles of this Issue 1/2020

Journal of Medical Case Reports 1/2020 Go to the issue